Recida Therapeutics

Recent Finacing

Series A

Recent Raise

$8.5M

Recida Therapeutics is a Menlo Park biopharmaceutical company developing RC-01, an IND-stage LpxC inhibitor for multidrug-resistant gram-negative infections, and managing global licensing and China development partnerships.

Founded 2016

California, United States

1-10

Private

recidatherapeutics.com

Highlights

Focus Areas

Biotechnology

Health Care

Recent Investors

Financials

$8.5M

Total Raised

1

Funding round

1

Investor

Team

Upgrade to view the team

See the team members at Recida Therapeutics.